Co-Located Conference AgendasCellTech India 2015 | Current Trends in Antibody Drug Conjugates | 
Monday, 2 March 201508:00 | Registration | 09:00 | Inauguration | |
Plenary Session |
| | 09:15 |  | Keynote Presentation Biotech Industrial Process : How Science, Technology and Market Demand meet
Alain Bernard, Vice President, UCB Pharma SA, Belgium
This presentation will highlight the Novel Strategies developed by Pharmaceutical Industry to improve Manufacturing process. It will focus on the safe implementation of Biotechnology Process changes along with maintaining product quality and comparability which has eliminated concerns of lack of capacities. Further, it will discuss the new challenges facing the industry with novel product formats and novel therapy paradigms. |
| 10:15 | Coffee Break and Networking Session | |
SESSION 1: Strategies in ADC Synthesis and Characterization/ Session Chair: Ajay Kumar Gupta |
| | 10:45 | Challenges and Opportunities in the Synthesis of Antibody Drug Conjugate Payloads
Jeremy Parker, Project Leader, AstraZeneca, United Kingdom
In this presentation, process
chemistry including route design and process design will be discussed for
preparation of Antibody Drug Conjugates Payloads. Further, this talk will also
explain how principal component analysis can be used to analyse known lists of
available cytotoxic molecules which promotes the use of payloads that target
chemotherapeutic mechanisms as well as identifying those which are structurally
simple and commercially available. | 11:25 | Antibody Drug Conjugates towards a Novel Approach and their Characteristics for Efficient Cancer Therapeutics: Future Prospects and Challenges
G Praveen Kumar, Professor & Principal, Sahasra Institute of Pharmaceutical Sciences, India
| 12:05 | | 13:05 | Lunch Break and Networking Session | |
SESSION 2: Designing Antibody Drug Conjugates/ Session Chair: Mark Wright |
| | 14:05 |  | Keynote Presentation Design and Generation of Site-Specific ADCs
Dimiter Dimitrov, Head/Senior Investigator, National Institutes of Health, United States of America
This
Keynote Talk will give an overview about
the current state of the ADC field and will discuss in more details
site-specific conjugation which has certain advantages compared to random
conjugation. A number of methods for
site-specific conjugation will be discussed including engineering sites for
conjugations, using naturally occurring sites for conjugation and enzymatic vs
chemical methods for generation of site-specific ADCs. Conjugation of
antibodies with small molecules through carbohydrates will be discussed in more
details and latest results will be presented including generation of ADCs
against cancer-related targets. |
| 15:05 | Development of Antibody-BFCA Conjugates for Radioimmunotherapy of Cancer
Tapas Das, Scientific Officer, Bhabha Atomic Research Centre, India
| 15:45 | Coffee Break and Networking Session | 16:15 | Incorporation of Homo-Bi-Functional Spacer via Hydrazone and Diimide Bond between Hapten-Protein Conjugate
Tulsidas Shrivastav, Professor, National Institute of Health & Family Welfare, India
This talk will focus on development of
conjugation chemistry for production of conjugated molecules. It will
specifically describe coupling of hapten to protein through homo-bi-functional spacer via
hydrazone and diimide bond. Further, it will discuss the importance of the Incorporation of Labile Bond (hydrazone) in
ADC along with the strategy that may be adopted for generation of ADC. | 16:55 |  Technology Spotlight:
Changing Landscape of Antibody Drug Conjugates: A CRO Perspective
Priyaranjan Pattanaik, Associate Research Director, Syngene International Ltd
| 17:25 | End of First Day of Conference |
Tuesday, 3 March 2015 |
SESSION 3: Development and Manufacture of ADC/ Session Chair: Dimiter Dimitrov |
| | 09:30 | Generation of an Optimal Antibody-Drug Conjugate for Oncology Therapy: Evolving Guiding Principles
Madan Katragadda, Senior Principal Scientist, Pfizer, United States of America
This presentation will discuss the principles
involved in generation of ADCs for Oncology Therapy. Further, it will focus on engineering and optimization of tumor targeting antibody vehicle,
conjugation strategy, and chemistry of linker-payload. Factors that guide the optimization
of antibody vehicle to suit the linker-payload and conjugation chemistry will
also be discussed. | 10:10 | Smooth Antibody Drug Conjugate Development and Manufacturing
Mark Wright, Site Lead, Piramal Healthcare UK Ltd, United Kingdom
This presentation will give an Overview of ADC manufacturing along with Process development
considerations for Cysteine and Lysine conjugations. Further, Case study
looking at the design and testing of ADC development candidates will be
discussed. | 10:50 | Coffee Break and Networking Session | |
SESSION 4: Nanotechnology for Delivery of ADCs/ Session Chair: Jeremy Parker |
| | 11:20 | Nanotheranostic Systems for Pancreatic Cancer: Therapeutic Potential and Challenges
Preeti Nigam Joshi, INSPIRE Faculty, National Chemical Laboratory, India
In
this presentation, different strategies for selective delivery of nano based chemotherapeutics
to pancreatic cancer site and simultaneous imaging (theranostics) will be
described. ADCs, siRNA and ligand receptor based multifunctional nanoconjugates
and their therapeutic potential against this deadly cancer will be discussed. The
other part of the discussion will be focused on the major challenges associated
with successful clinical translation of nanotheranostic systems and their
possible solutions for early diagnosis of cancers. | 12:00 | Engineering of Antibody Conjugated Drug Loaded Nanoparticle for Targeted Drug Delivery
Ajay Kumar Gupta, Director & Head, Confederation of Indian Industry, India
In
this presentation, various selective targeting strategies using nanoparticles
for achieving effective cancer detection and treatment would be discussed.
Various targeting moieties which may be used as 'escort' molecules to specific
tumor tissues including peptides and antibodies etc would be discussed. In
addition, different methods of conjugating the functional moieties to nanoparticles
and strategies for optimizing the nanoparticle surfaces for in vivo applications would
be discussed. | 12:40 | Lunch Break and Networking Session | |
SESSION 5: Approaches for Targeting ADCs |
| | 13:40 | Site-Specific Antibody Drug Conjugation through Carbohydrate
Dimiter Dimitrov, Head/Senior Investigator, National Institutes of Health, United States of America
| 14:10 | Use of Abrin-Antibody Conjugates in Cell-Targeted Killing
Anjali Karande, Professor, Indian Institute of Science, India
| 14:50 | Novel Drug Discovery on Antibody-Drug Conjugate System
Rajkumar Halder, Scientist E, Translational Health Science and Technology Institute, India
This talk will focus on how to develop a novel antibody-drug
conjugate system through expanding
genetic code and its superiority over other ADC systems. It will also
include strategies and approaches
for selecting an antibody,
linker, toxin/s and payload for the development of a novel ADC system from bench side to bedside for the treatment of
Her2+ breast cancer though strong collaboration between academia and
industries. | 15:30 | Bioanalytical & Pre-Clinical Development Strategies for ADCs
Sanghamitra Bhattacharjee, Senior Scientist, Theramyt Novobiologics Pvt. Ltd, India
In this talk, development of trastuzumab-emtansine will be discussed as a case study. Further,
it will throw light on Product Development and Pre-Clinical Strategies for
ADCs. | 16:00 | Coffee Break and Networking Session | |
Panel Discussion: Safety & Efficacy of Antibody Drug Conjugates- Where are We Currently? |
| | 16:30 | Safety & Efficacy of Antibody Drug Conjugates- Where are We Currently?
Palani Palaniappan, Vice President & Head, Takeda Pharmaceuticals International Co., United States of America
Ajay
Kumar Gupta, Senior Counsellor / Director & Head, Confederation of
Indian Industry, India
Jeremy
Parker, Principal Scientist, AstraZeneca, United Kingdom
Mark
Wright, Site Lead, Piramal Healthcare UK Ltd, United Kingdom | 17:00 | End of Conference |
|
Add to Calendar ▼2015-03-02 00:00:002015-03-03 00:00:00Europe/LondonCurrent Trends in Antibody Drug ConjugatesCurrent Trends in Antibody Drug Conjugates in Bangalore, IndiaBangalore, IndiaSELECTBIOenquiries@selectbiosciences.com
